Tivozanib
Sign in to save this workspacePrimary targets: KDR_VEGFR2 · FDA status: FDA Approved
Selectivity scorecard
KISS
92.42
Gini
0.673
CATDS
0.012
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Tivozanib. Strongest target: RET at 99.7% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | RET | 99.7% | 0.3% |
| 2 | C_KIT | 99.4% | 0.6% |
| 3 | KDR_VEGFR2 | 99.3% | 0.7% |
| 4 | FLT4_VEGFR3 | 99.3% | 0.7% |
| 5 | LYN | 99.3% | 0.7% |
| 6 | DDR2 | 99.3% | 0.7% |
| 7 | FMS | 98.6% | 1.4% |
| 8 | EPHA6 | 98.3% | 1.7% |
| 9 | EPHB2 | 98.0% | 2.0% |
| 10 | C_MET | 97.7% | 2.4% |
| 11 | FLT1_VEGFR1 | 97.6% | 2.4% |
| 12 | LCK | 97.5% | 2.5% |
| 13 | BRK | 97.2% | 2.8% |
| 14 | FRK_PTK5 | 97.2% | 2.8% |
| 15 | HCK | 97.1% | 2.9% |
| 16 | DDR1 | 97.1% | 2.9% |
| 17 | PDGFRA | 96.9% | 3.1% |
| 18 | FGR | 96.6% | 3.4% |
| 19 | LOK_STK10 | 96.2% | 3.8% |
| 20 | TRKC | 96.1% | 3.9% |
Selectivity landscape
Where Tivozanib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Tivozanib.
Annotations
Sign in to read and post annotations.
Loading…